دورية أكاديمية
أعرض في EDS

CB2 Cannabinoid Receptor as a Potential Target in Myocardial Infarction: Exploration of Molecular Pathogenesis and Therapeutic Strategies.

التفاصيل البيبلوغرافية
العنوان: CB2 Cannabinoid Receptor as a Potential Target in Myocardial Infarction: Exploration of Molecular Pathogenesis and Therapeutic Strategies.
المؤلفون: More SA; Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India., Deore RS; Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India., Pawar HD; Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India., Sharma C; Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates., Nakhate KT; Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India., Rathod SS; Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India., Ojha S; Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates., Goyal SN; Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jan 30; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 30.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Cannabinoids*/pharmacology , Cannabinoids*/therapeutic use , Cannabinoids*/metabolism , Myocardial Infarction*/drug therapy , Myocardial Infarction*/genetics , Myocardial Infarction*/metabolism , Receptor, Cannabinoid, CB1*/genetics , Receptor, Cannabinoid, CB1*/metabolism, Humans ; Endocannabinoids/metabolism ; Myocardium/metabolism ; Receptor, Cannabinoid, CB2/genetics ; Receptor, Cannabinoid, CB2/metabolism ; Receptors, Cannabinoid/metabolism ; Dronabinol/pharmacology
مستخلص: The lipid endocannabinoid system has recently emerged as a novel therapeutic target for several inflammatory and tissue-damaging diseases, including those affecting the cardiovascular system. The primary targets of cannabinoids are cannabinoid type 1 (CB1) and 2 (CB2) receptors. The CB2 receptor is expressed in the cardiomyocytes. While the pathological changes in the myocardium upregulate the CB2 receptor, genetic deletion of the receptor aggravates the changes. The CB2 receptor plays a crucial role in attenuating the advancement of myocardial infarction (MI)-associated pathological changes in the myocardium. Activation of CB2 receptors exerts cardioprotection in MI via numerous molecular pathways. For instance, delta-9-tetrahydrocannabinol attenuated the progression of MI via modulation of the CB2 receptor-dependent anti-inflammatory mechanisms, including suppression of pro-inflammatory cytokines like IL-6, TNF-α, and IL-1β. Through similar mechanisms, natural and synthetic CB2 receptor ligands repair myocardial tissue damage. This review aims to offer an in-depth discussion on the ameliorative potential of CB2 receptors in myocardial injuries induced by a variety of pathogenic mechanisms. Further, the modulation of autophagy, TGF-β/Smad3 signaling, MPTP opening, and ROS production are discussed. The molecular correlation of CB2 receptors with cardiac injury markers, such as troponin I, LDH1, and CK-MB, is explored. Special attention has been paid to novel insights into the potential therapeutic implications of CB2 receptor activation in MI.
References: Cardiovasc Res. 2002 Aug 15;55(3):619-25. (PMID: 12160959)
Basic Res Cardiol. 2014 Jul;109(4):425. (PMID: 24980781)
Stroke. 2017 Jan;48(1):204-212. (PMID: 27899748)
Br J Pharmacol. 2003 Jun;139(4):805-15. (PMID: 12813004)
Int J Biochem Cell Biol. 2005 Sep;37(9):1746-51. (PMID: 15950518)
Life Sci. 2018 Dec 15;215:96-105. (PMID: 30403990)
Chem Biol Interact. 2017 May 25;270:9-14. (PMID: 28411027)
Biochem Biophys Res Commun. 2017 Oct 14;492(2):262-268. (PMID: 28830813)
Br J Pharmacol. 2012 Sep;167(2):313-23. (PMID: 22612332)
Chem Biol Interact. 2019 Jan 5;297:16-24. (PMID: 30343038)
Circulation. 1995 Oct 1;92(7):1866-75. (PMID: 7671371)
Crit Care Med. 2002 May;30(5):1071-82. (PMID: 12006805)
Pharmacology. 2014;94(1-2):1-12. (PMID: 25171128)
Pharmacol Res. 2008 Aug;58(2):88-111. (PMID: 18620057)
Cell Signal. 2012 May;24(5):981-90. (PMID: 22286106)
J Pharmacol Sci. 2006 Oct;102(2):155-66. (PMID: 17031075)
Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28. (PMID: 16829982)
Antioxid Redox Signal. 2015 May 10;22(14):1230-42. (PMID: 25330054)
Arthritis Rheum. 2009 Apr;60(4):1129-36. (PMID: 19333940)
Circulation. 1998 Aug 18;98(7):699-710. (PMID: 9715863)
Front Cardiovasc Med. 2022 Oct 14;9:968014. (PMID: 36312282)
J Am Coll Cardiol. 2002 Apr 3;39(7):1229-35. (PMID: 11923051)
Cell Commun Signal. 2020 Jan 15;18(1):9. (PMID: 31941496)
Front Cell Neurosci. 2017 Jan 04;10:294. (PMID: 28101004)
Prog Neurobiol. 2018 Apr - May;163-164:98-117. (PMID: 29331396)
J Cardiovasc Pharmacol. 2020 Jan;75(1):54-63. (PMID: 31815823)
Atherosclerosis. 2014 Mar;233(1):55-63. (PMID: 24529123)
Cardiovasc Res. 2019 Mar 1;115(3):602-613. (PMID: 30295758)
J Biol Chem. 2012 Jan 6;287(2):1198-209. (PMID: 22102284)
Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H909-18. (PMID: 17434980)
Open Cardiovasc Med J. 2010 Dec 23;4:302-12. (PMID: 21339899)
J Am Coll Cardiol. 2018 Apr 17;71(15):1696-1706. (PMID: 29650126)
Biosci Rep. 2019 Apr 26;39(4):. (PMID: 30923227)
Circulation. 2001 Jul 17;104(3):365-72. (PMID: 11457759)
Br J Pharmacol. 2012 Feb;165(3):754-64. (PMID: 21797845)
Biomed Pharmacother. 2018 May;101:379-390. (PMID: 29501041)
J Am Coll Cardiol. 2007 Aug 7;50(6):528-36. (PMID: 17678736)
EMBO J. 1999 Aug 16;18(16):4446-54. (PMID: 10449410)
Cell Physiol Biochem. 2015;36(3):917-29. (PMID: 26088607)
Cell Physiol Biochem. 2015;37(2):666-76. (PMID: 26344923)
World J Cardiol. 2011 Jun 26;3(6):186-200. (PMID: 21772945)
J Mol Cell Cardiol. 2015 Aug;85:249-61. (PMID: 26093151)
Immunol Lett. 2023 Dec;264:17-24. (PMID: 37918639)
Brain Behav Immun. 2018 Feb;68:224-237. (PMID: 29079445)
J Mol Cell Cardiol. 2009 May;46(5):612-20. (PMID: 19162037)
Cell Physiol Biochem. 2016;39(4):1521-36. (PMID: 27614871)
Mol Cell Biochem. 2020 Nov;474(1-2):1-14. (PMID: 32681290)
Hepatology. 2020 Apr;71(4):1391-1407. (PMID: 31469200)
Diagn Pathol. 2013 Apr 30;8:68. (PMID: 23631751)
Cardiovasc Res. 2000 Aug 18;47(3):446-56. (PMID: 10963718)
Nat Rev Cardiol. 2014 May;11(5):255-65. (PMID: 24663091)
Front Biosci (Landmark Ed). 2022 Apr 1;27(4):114. (PMID: 35468673)
Oxid Med Cell Longev. 2021 Jan 28;2021:6626484. (PMID: 33574977)
Bioengineered. 2022 Mar;13(3):5779-5791. (PMID: 35188441)
J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):46-56. (PMID: 28466688)
J Diet Suppl. 2020;17(5):625-650. (PMID: 32677481)
J Immunol. 1999 Sep 1;163(5):2858-66. (PMID: 10453032)
Biochemistry (Mosc). 2013 Dec;78(13):1447-65. (PMID: 24490734)
Antioxid Redox Signal. 2009 Jun;11(6):1415-52. (PMID: 19061437)
J Cardiovasc Pharmacol. 2012 Apr;59(4):301-7. (PMID: 22113346)
J Immunol. 2015 Jan 15;194(2):499-503. (PMID: 25505286)
Biol Sex Differ. 2018 Nov 27;9(1):50. (PMID: 30482253)
Life Sci. 2021 May 1;272:119228. (PMID: 33607150)
Transl Res. 2016 Jan;167(1):152-66. (PMID: 26241027)
J Cardiovasc Pharmacol. 2014 Nov;64(5):420-30. (PMID: 24979612)
Curr Drug Targets. 2015;16(4):334-41. (PMID: 25469884)
Am J Physiol Heart Circ Physiol. 2004 Apr;286(4):H1408-15. (PMID: 14670820)
Eur J Biochem. 1995 Aug 15;232(1):54-61. (PMID: 7556170)
Circ Res. 2002 Oct 18;91(8):719-26. (PMID: 12386149)
Pathol Int. 2020 Jun;70(6):309-322. (PMID: 32166823)
Toxicol Lett. 2019 Oct 1;313:77-90. (PMID: 31220554)
Oncogene. 2004 Apr 12;23(16):2861-74. (PMID: 15077149)
J Adv Pharm Technol Res. 2011 Oct;2(4):236-40. (PMID: 22247890)
Nature. 1993 Sep 2;365(6441):61-5. (PMID: 7689702)
J Clin Pathol. 2003 Mar;56(3):194-9. (PMID: 12610097)
Life Sci. 2015 Oct 1;138:8-17. (PMID: 25447445)
Neurotox Res. 2018 May;33(4):846-855. (PMID: 29134561)
J Cardiol. 2019 Sep;74(3):258-266. (PMID: 30898480)
Br J Pharmacol. 2016 Aug;173(15):2402-18. (PMID: 27186946)
Oncotarget. 2017 May 4;8(39):64853-64866. (PMID: 29029396)
Am J Pathol. 1995 Feb;146(2):419-28. (PMID: 7856752)
Front Immunol. 2017 May 16;8:553. (PMID: 28559895)
Can J Physiol Pharmacol. 2014 Mar;92(3):205-14. (PMID: 24593785)
Diabetes. 2012 Mar;61(3):716-27. (PMID: 22315315)
Sci Rep. 2016 Jun 27;6:28806. (PMID: 27346657)
Curr Vasc Pharmacol. 2005 Jul;3(3):209-14. (PMID: 16026317)
FASEB J. 2007 Jun;21(8):1788-800. (PMID: 17327359)
J Cardiovasc Pharmacol Ther. 2016 May;21(3):262-72. (PMID: 26487546)
J Cardiovasc Pharmacol. 2006 May;47(5):650-5. (PMID: 16775503)
JAMA. 1999 May 12;281(18):1718-21. (PMID: 10328072)
J Leukoc Biol. 2007 Dec;82(6):1382-9. (PMID: 17652447)
Diabetes Metab Res Rev. 2011 May;27(4):331-40. (PMID: 21309057)
Transl Stroke Res. 2015 Dec;6(6):467-77. (PMID: 26376816)
Circ Res. 2000 Nov 10;87(10):840-4. (PMID: 11073878)
Cell Physiol Biochem. 2016;38(2):571-88. (PMID: 26845171)
FASEB J. 2009 Jul;23(7):2120-30. (PMID: 19246487)
PLoS One. 2017 Nov 29;12(11):e0188748. (PMID: 29186197)
Cell Mol Life Sci. 2016 Dec;73(23):4449-4470. (PMID: 27402121)
J Am Coll Cardiol. 2014 Jun 24;63(24):2742-4. (PMID: 24681139)
Recent Pat CNS Drug Discov. 2016;10(2):90-112. (PMID: 27364363)
Front Cardiovasc Med. 2023 Jan 24;10:1094188. (PMID: 36760567)
Nat Rev Cardiol. 2010 Feb;7(2):77-86. (PMID: 20065951)
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):532-40. (PMID: 22740013)
J Tehran Heart Cent. 2021 Apr;16(2):68-74. (PMID: 35082874)
Neuromolecular Med. 2014 Sep;16(3):620-42. (PMID: 24929655)
J Biol Chem. 1976 Aug 25;251(16):5069-77. (PMID: 134035)
Geroscience. 2022 Jun;44(3):1727-1741. (PMID: 35460032)
J Mol Cell Cardiol. 2010 Jun;48(6):1187-93. (PMID: 19931541)
Vasc Health Risk Manag. 2005;1(3):183-98. (PMID: 17319104)
Am J Pathol. 2004 Feb;164(2):665-77. (PMID: 14742270)
Eur J Pharmacol. 2010 Dec 15;649(1-3):285-92. (PMID: 20868672)
Curr Atheroscler Rep. 2014 Apr;16(4):401. (PMID: 24504549)
Front Pharmacol. 2018 Nov 06;9:1292. (PMID: 30459625)
Cardiovasc Res. 2007 Jul 15;75(2):315-26. (PMID: 17568574)
J Mol Cell Cardiol. 2003 Apr;35(4):339-41. (PMID: 12689812)
J Mol Cell Cardiol. 2015 May;82:84-92. (PMID: 25771143)
Eur J Pharmacol. 2021 Dec 15;913:174645. (PMID: 34800467)
Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H87-95. (PMID: 16155108)
Cardiovasc Res. 2007 May 1;74(2):196-206. (PMID: 17376414)
Adv Pharmacol. 2017;80:329-366. (PMID: 28826540)
Br J Pharmacol. 2008 Jan;153(2):252-62. (PMID: 18026124)
Nitric Oxide. 2006 Mar;14(2):169-79. (PMID: 16111903)
Mol Cell Biochem. 2006 Feb;283(1-2):75-83. (PMID: 16444588)
Jpn Heart J. 2004 Mar;45(2):183-93. (PMID: 15090695)
Vasc Health Risk Manag. 2019 Jan 17;15:1-10. (PMID: 30697054)
Front Cardiovasc Med. 2022 Jun 01;9:925923. (PMID: 35722128)
Oxid Med Cell Longev. 2014;2014:260429. (PMID: 25101151)
Am J Pathol. 2011 Mar;178(3):1153-66. (PMID: 21356367)
Front Pharmacol. 2019 May 31;10:551. (PMID: 31214022)
Crit Care Med. 2002 Feb;30(2):417-21. (PMID: 11889322)
Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8. (PMID: 17660390)
Life Sci. 2015 Oct 1;138:18-28. (PMID: 25497711)
Free Radic Biol Med. 2010 Feb 1;48(3):457-67. (PMID: 19969072)
Front Pharmacol. 2021 Feb 02;12:636134. (PMID: 33603675)
Ann Intern Med. 2005 May 3;142(9):786-91. (PMID: 15867411)
J Mol Med (Berl). 2013 Jul;91(7):811-23. (PMID: 23636507)
NeuroImmune Pharm Ther. 2023 Oct 16;2(4):387-400. (PMID: 38116176)
Biomedicines. 2023 Sep 26;11(10):. (PMID: 37893016)
Life (Basel). 2022 Apr 22;12(5):. (PMID: 35629293)
Circulation. 2003 Nov 11;108(19):2393-9. (PMID: 14557369)
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3270-5. (PMID: 11854472)
Br J Pharmacol. 2019 Apr;176(7):890-905. (PMID: 30707759)
J Electrocardiol. 2018 Jan - Feb;51(1):8-14. (PMID: 28928045)
J Med Chem. 2017 Aug 24;60(16):7067-7083. (PMID: 28726401)
Planta Med. 2003 Aug;69(8):757-64. (PMID: 14531028)
Biomolecules. 2019 Jul 31;9(8):. (PMID: 31370242)
Sci China Life Sci. 2014 Feb;57(2):201-8. (PMID: 24430557)
J Pharmacol Exp Ther. 2008 Feb;324(2):475-83. (PMID: 18029545)
Mol Cell Biol. 2005 Nov;25(21):9554-75. (PMID: 16227605)
Sci Rep. 2017 Nov 23;7(1):16169. (PMID: 29170454)
Cell Physiol Biochem. 2016;39(3):827-36. (PMID: 27497782)
Circulation. 2010 Sep 14;122(11 Suppl):S179-84. (PMID: 20837911)
Int J Mol Sci. 2022 Mar 20;23(6):. (PMID: 35328769)
Clin Cardiol. 1986 Dec;9(12):597-9. (PMID: 3780075)
Medicines (Basel). 2018 May 28;5(2):. (PMID: 29843404)
Life Sci. 2007 Aug 16;81(10):779-93. (PMID: 17707439)
Life Sci. 2007 Oct 13;81(17-18):1373-80. (PMID: 17931662)
Circ Res. 2007 Mar 2;100(4):474-88. (PMID: 17332438)
Antioxid Redox Signal. 2014 Jul 1;21(1):66-85. (PMID: 24483238)
Circulation. 2001 Jul 17;104(3):253-6. (PMID: 11457740)
Biol Trace Elem Res. 2003 Winter;96(1-3):61-9. (PMID: 14716086)
Trends Endocrinol Metab. 2015 Aug;26(8):422-9. (PMID: 26160707)
Br J Pharmacol. 2001 Feb;132(4):793-6. (PMID: 11181418)
Atherosclerosis. 2014 Jul;235(1):213-22. (PMID: 24858340)
معلومات مُعتمدة: 12R104 and 12R121 United Arab Emirates University
فهرسة مساهمة: Keywords: CB2 receptors; ROS; cardiac markers; cytokines; myocardial infarction
المشرفين على المادة: 0 (Cannabinoids)
0 (Endocannabinoids)
0 (Receptor, Cannabinoid, CB1)
0 (Receptor, Cannabinoid, CB2)
0 (Receptors, Cannabinoid)
7J8897W37S (Dronabinol)
تواريخ الأحداث: Date Created: 20240210 Date Completed: 20240223 Latest Revision: 20240223
رمز التحديث: 20240223
مُعرف محوري في PubMed: PMC10855244
DOI: 10.3390/ijms25031683
PMID: 38338960
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25031683